MOMETASONE SUMMARY
Mometasone furoate ointment USP, 0.1% contains mometasone furoate USP for topical use. Mometasone furoate USP is a synthetic corticosteroid with anti-inflammatory activity.
Mometasone furoate ointment USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or older.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Mometasone (Mometasone Topical)
Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. [2011.10]
OBJECTIVE: To assess the effects of long-term mometasone furoate delivered via a dry powder inhaler (MF-DPI) on growth velocity and hypothalamic-pituitary-adrenal axis function in children with asthma... CONCLUSIONS: One year of treatment with a total daily dose of 100 mug of MF-DPI in the morning resulted in no significant difference, whereas a total daily dose of 200 mug of MF-DPI was associated with some changes in growth velocity when compared with placebo. The differences in growth velocity, and the absence of drug-related cortisol effects, support the use of a total daily dose of 100 mug of MF-DPI in children aged 4-9 years with mild persistent asthma.
Dysphagia and quality of life may improve with mometasone treatment in patients with eosinophilic esophagitis: a pilot study. [2011.10]
OBJECTIVE: The treatment of adult patients with eosinophilic esophagitis remains challenging. The aim was to assess dysphagia and health-related quality of life (HRQL) using validated scales and questionnaires before and after treatment with mometasone furoate... CONCLUSION: The dysphagia and impaired HRQL found in untreated patients with eosinophilic esophagitis improved significantly after 2 months of mometasone furoate treatment. A randomized placebo-controlled trial is warranted to assess causality. The scales and questionnaires used are sensitive instruments appropriate for symptom surveillance in individuals with eosinophilic esophagitis.
Application of mometasone spray to reduce sore throat after tracheal intubation. [2011.08]
CONCLUSION: Application of mometasone spray reduces postoperative sore throat after tracheal intubation.
The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. [2011.06]
BACKGROUND: The efficacy of oral montelukast in chronic asthma is well established. Montelukast is also an effective adjunctive therapy to inhaled corticosteroids (ICS) in asthma uncontrolled on ICS alone. Inhaled montelukast was recently shown to provide significant bronchodilation compared with placebo in patients with chronic asthma. The purpose of this study was to evaluate the efficacy of inhaled montelukast added to inhaled mometasone... CONCLUSION: Inhaled montelukast plus inhaled mometasone was significantly more effective than placebo plus inhaled mometasone in improving FEV(1), symptoms, asthma control, and blood eosinophil count.
Mometasone furoate effect on acute skin toxicity in breast cancer patients receiving radiotherapy: a phase III double-blind, randomized trial from the North Central Cancer Treatment Group N06C4. [2011.04.01]
CONCLUSION: Patients receiving daily MMF during radiotherapy might experience reduced acute skin toxicity compared with patients receiving placebo. Copyright (c) 2011 Elsevier Inc. All rights reserved.
Clinical Trials Related to Mometasone (Mometasone Topical)
A Study of Mometasone Furoate Nasal Spray in Perennial Allergic Rhinitis (Study P03748)(COMPLETED) [Completed]
This is a multicenter, randomized, double-blind within the dose level, parallel group
comparison of mometasone furoate nasal spray in subjects with perennial allergic rhinitis to
examine the minimal effective dose, the recommended dose, and the dosing regimen.
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED) [Completed]
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the
anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol
fumarate (MF/F) metered dose inhaler (MDI) formulation and medium dose mometasone furoate
(MF) dry powder inhaler (DPI) and MDI formulations in adults and adolescents with persistent
allergic asthma.
Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma [Completed]
Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation
transporters expressed by non-neuronal cells, thereby interfering with the inactivation of
the organic cations by intracellular enzymes. Beta2-adrenergic agonists are organic cations,
and the concentration of inhaled beta2-adrenergic agonists at beta2-adrenergic receptor
sites on smooth muscle is likely to be increased by inhaled glucocorticosteroids (ICS) by
the ICS' effect on the glucocorticosteroid-sensitive organic cation transporters. The
investigators have shown in human airway vascular smooth muscle cells that the
glucocorticosteroid action on organic cation uptake occurs within minutes, does not involve
gene transcription or protein synthesis, is not mediated through classical steroid
receptors, and is cell membrane-linked.
In the present proposal, the investigators wish to use different single doses of
mometasone, a clinically effective ICS, administered with or at different times before
albuterol inhalation in subjects with moderate persistent asthma who are obstructed at the
time of study.
With this approach the investigators will test the hypothesis that a single inhalation of
mometasone causes an acute, transient, dose-dependent potentiation of beta2-adrenergic
bronchodilation.
If the hypothesis that a single dose of mometasone acutely potentiates beta2-adrenergic
bronchodilation is correct, the results would have a significant impact on treatment
strategies involving ICSs and beta2-adrenergic agonists in patients with asthma.
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512) [Completed]
This study was conducted to see if mometasone nasal spray is efficaceous for the treatment
of perennial allergic rhinitis. Patients will be randomized to active mometasone, placebo
mometasone, active fluticasone, or placebo fluticasone.
Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy [Withdrawn]
Obstructive sleep apnea (OSA) in children is a disorder of breathing during sleep
characterized by prolonged partial upper airway obstruction and/or intermittent complete
obstruction (obstructive apnea) that disrupts normal breathing during sleep1. The condition
occurs in 2-5% of children and can occur at any age, but it is most common in children
between the ages of 2 to 62,3. Untreated OSA is associated with lung disease, heart
disease, growth delay, poor learning and behavioral problems such as inattention and
hyperactivity. The most common underlying risk factor for the development of OSA is
enlargement of tonsils and adenoids. Given the potential risk of complications associated
with surgery of the tonsils and adenoids, medications to shrink the adenoids without
requiring surgery have been considered, in particular intranasal corticosteroids (INCSs)
which is a nose spray. A recent Cochrane systematic review suggested a short-term benefit
of INCSs in children with mild to moderate OSA4. The authors recommended that further
randomised controlled studies were required to evaluate the efficacy of INCSs in children
with OSA. In particular they recommended that future studies should employ sleep studies to
look for any improvement with INCSs, and should include children with more severe OSA, as
these are the patients at the greatest risk of complications of surgery and would benefit
most from a non-surgical treatment. The purpose of this study is therefore to explore the
efficacy of INCSs in children with the full spectrum of OSA severity, including sleep study
analysis., and longer term follow-up.
|
|
|
|
Page last updated: 2011-12-09
|
